How gene tests and old-school scores team up to guess prostate cancer’s next move

Doctors have two common tools to guess if prostate cancer will come back after surgery. One tool, CAPRA, looks at PSA numbers, how fast the cancer is growing, and whether it has spread. The other, called CAPRA-S, does the same but after the tumor is removed. Both tools are handy, but they ignore the actual biology of the cancer cells. They can’t read DNA or spot aggressive mutations that might make the cancer return. That’s where gene testing steps in. A newer test, GPS, reads 17 different genes inside the tumor. It gives a score that shows how fast the cancer might grow or spread. The study combined GPS with the older CAPRA numbers to create two new scores: CAPRA-G and CAPRA-SG. These new scores still use PSA and other clinical facts, but they add the gene test result to make a better prediction. Early data suggests the combined scores do a stronger job of telling which patients are at higher risk of their cancer returning.Not everyone agrees gene tests should be routine, though. The cost of GPS can be high, and insurance doesn’t always cover it. Also, doctors already have years of experience using CAPRA and CAPRA-S. Adding gene results might be useful, but it could also create confusion if the two systems don’t match. Patients might get mixed messages about their risk. Another question is whether these new scores will change how doctors treat patients. If the combined score says a man is at low risk, will surgeons operate differently? Or will they still follow the same steps? The study doesn’t say yet. More research is needed to see if CAPRA-G and CAPRA-SG actually improve survival rates or just add another layer of data that doesn’t matter.